NEW YORK, NY / ACCESS Newswire / March 15, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...
The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...